Advanced search
Publication Cover
Expert Opinion on Drug Metabolism & Toxicology Volume 17, 2021 - Issue 9
Submit an article Journal homepage
3,897
Views
1
CrossRef citations to date
0
Altmetric
Original research

Pharmacokinetic and pharmacodynamic evaluation of the new prolonged-release leuprorelin acetate microspheres for injection compared with Enantone® in healthy Chinese male volunteers

Huan Zhoua First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China;b School of Pharmacy, Bengbu Medical University, Bengbu, Anhui, China;c School of Public Foundation, Bengbu Medical University, Bengbu, Anhui, ChinaORCID Iconhttps://orcid.org/0000-0002-9396-8787View further author information
ORCID Icon,
Jing Xiea First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, ChinaView further author information
,
Xingyu Zhua First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China;b School of Pharmacy, Bengbu Medical University, Bengbu, Anhui, ChinaCorrespondence[email protected]
View further author information
,
Xiaoyi Lid Zhaoke Pharmaceutical (Hefei) Co., Ltd, Hefei, Anhui, ChinaView further author information
,
Xiaohui Yud Zhaoke Pharmaceutical (Hefei) Co., Ltd, Hefei, Anhui, ChinaView further author information
,
Yong Zhangd Zhaoke Pharmaceutical (Hefei) Co., Ltd, Hefei, Anhui, ChinaView further author information
,
Yue Sua First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China;c School of Public Foundation, Bengbu Medical University, Bengbu, Anhui, ChinaView further author information
,
Cuixia Hea First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China;b School of Pharmacy, Bengbu Medical University, Bengbu, Anhui, ChinaView further author information
,
Minhui Zhua First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China;b School of Pharmacy, Bengbu Medical University, Bengbu, Anhui, ChinaView further author information
,
Xiao li Lia First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, ChinaView further author information
,
Yuanyuan Liua First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, ChinaView further author information
,
Juan Chena First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, ChinaView further author information
,
Dongmei Chenga First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, ChinaView further author information
,
Mengmeng Chena First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, ChinaView further author information
,
Ying Wanga First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, ChinaView further author information
,
Qin Gea First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, ChinaView further author information
,
Ling Fana First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, ChinaView further author information
,
Ying Wanga First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, ChinaView further author information
,
ZhongHuan Shaoa First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, ChinaView further author information
,
Bingyan Liua First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, ChinaView further author information
,
Rongfang Shana First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, ChinaView further author information
,
Xiangrong Daid Zhaoke Pharmaceutical (Hefei) Co., Ltd, Hefei, Anhui, ChinaCorrespondence[email protected]
View further author information
,
Hongju Wanga First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, ChinaCorrespondence[email protected]
View further author information
&
Huaxue Wanga First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China;e Department of Critical Care Medicine, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, ChinaCorrespondence[email protected]
View further author information
 show all
Pages 1149-1156 | Received 17 Apr 2021, Accepted 23 Jun 2021, Published online: 10 Aug 2021

References

  • Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2020;70(1):7–30.
  • Mohler JL, Antonarakis ES, Armstrong AJ, et al. Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17(5):479–505.
  • Dreicer R. The evolving role of hormone therapy in advanced prostate cancer. Clev Clin J Med. 2000;67(10):720–2, 725–6.
  • Mcleod DG. Hormonal therapy: historical perspective to future directions. Urology. 2003;61(2 Suppl 1):3–7.
  • ÉD S, Ferreira U, Matheus W, et al. Goserelin versus leuprolide in the chemical castration of patients with prostate cancer. Int Urol Nephrol. 2012;44(4):1039–1044.
  • Lepor H. Comparison of single-agent androgen suppression for advanced prostate cancer. Rev Urol. 2005;7 Suppl 5(Suppl5):S3–S12.
  • Lepor H, Shore ND. LHRH agonists for the treatment of prostate cancer: 2012. Rev Urol. 2012;14(1–2):1–12.
  • Limonta P, Marelli MM, Moretti RM. LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action. Expert Opin Investig Drugs. 2001;10(4):709–720.
  • Plosker GL, Brogden RN. Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders. Drugs. 1994;48(6):930–967.
  • Wilson AC, Meethal SV, Bowen RL, et al. Leuprolide acetate: a drug of diverse clinical applications. Expert Opin Investig Drugs. 2007;16(11):1851–1863.
  • Wang ST, Johnson SJ, Mitchell D, et al. Cost–effectiveness of elagolix versus leuprolide acetate for treating moderate-to-severe endometriosis pain in the USA. J Comp Eff Res. 2019;8(5):337–355.
  • Vatopoulou A, Roos E, Daniilidis A, et al. Long-term effects of treatment of central precocious puberty with gonadotropin-releasing hormone analogs every three months. Gynecol Endocrinol. 2020;36(12):1124–1126.
  • Klein KO, Freire A, Gryngarten MG, et al. Phase 3 trial of a small-volume subcutaneous 6-month duration leuprolide acetate treatment for central precocious puberty. J Clin Endocrinol Metab. 2020;105(10):e3660–e3671.
  • Crawford ED, Phillips JM. Six-month gonadotropin releasing hormone (GnRH) agonist depots provide efficacy, safety, convenience, and comfort. Cancer Manag Res. 2011;3:201–209.
  • Shore ND, Guerrero S, Sanahuja RM, et al. A new sustained-release, 3-month leuprolide acetate formulation achieves and maintains castrate concentrations of testosterone in patients with prostate cancer. Clin Ther. 2019;41(3):412–425.
  • Shore N, Mincik I, DeGuenther M, et al. A phase 3, open-label, multicenter study of a 6-month pre-mixed depot formulation of leuprolide mesylate in advanced prostate cancer patients. World J Urol. 2020;38(1):111–119.
  • Freitas CSMD, Soares AN. Efficacy of Leuprorelide acetate (Eligard®) in daily practice in Brazil: a retrospective study with depot formulations in patients with prostate cancer. Int Braz J Urol. 2020;46(3):383–389.
  • Bruneu-Avierinos Y, Monestier S, Tasei A-M. Granulomas induced by injections of leuprorelin acetate (Enantone®). Ann Dermatol Venereol. 2011;138(1):35–37.
  • Leitner JM, Mayr FB, Spiel AO, et al., The pharmacokinetics and pharmacodynamics of a new sustained-release leuprolide acetate depot compared to market references. Int J Clin Pharmacol Ther. 2008;46(8):407–414.
  • Marberger M, Kaisary AV, Shore ND, et al., Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a phase III, open-label, international multicenter study. Clin Ther. 2010;32(4):744–757.
  • Gillessen S, Omlin A, Attard G, et al. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol. 2015;26(8):1589–1604.
  • Bubley GJ. Is the flare phenomenon clinically significant? Urology. 2001;58(2 Suppl 1):5–9.
  • Yasukawa K, Sawamura D, Sugawara H, et al. Leuprorelin acetate granulomas: case reports and review of the literature. Brit J Dermatol. 2005;152(5):1045–1047.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.